Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH

Here are the Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Adipose tissue under microscope, adipose tissue macrophage infiltration and hepatocyte stress rash, brown adipose tissue and weight loss, adipose tissue macrophage infiltration and hepatocyte stress ball, adipose tissue macrophages, adipose tissue macrophage infiltration and the water, adipose tissue macrophage infiltration and hepatocyte ballooning, adipose tissue macrophage infiltration and hepatocyte stressless recliners, adipose tissue macrophage infiltration and hepatocyte nuclear.

Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH

Plasma growth differentiation factor-15 (GDF-15) levels increase with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) but the underlying mechanism remains poorly defined. Using male mouse models of obesity and MASLD, and biopsies from carefully-characterized patients regarding obesity, type 2 diabetes (T2D) and MASLD status, we identify adipose tissue (AT) as the key source of GDF-15 at onset of obesity and T2D, followed by liver during the progression towards metabolic dysfunction-associated steatohepatitis (MASH). Obesity and T2D increase GDF15 expression in AT through the accumulation of macrophages, which are the main immune cells expressing GDF15. Inactivation of Gdf15 in macrophages reduces plasma GDF-15 concentrations and exacerbates obesity in mice. During MASH development, Gdf15 expression additionally increases in hepatocytes through stress-induced TFEB and DDIT3 signaling. Together, these results demonstrate a dual contribution of AT an d liver to GDF-15 production in metabolic diseases and identify potential therapeutic targets to raise endogenous GDF-15 levels. © The Author(s) 2024.

Authors : L'homme L.; Sermikli B.P.; Haas J.T.; Fleury S.; Quemener S.; Guinot V.; Barreby E.; Esser N.; Caiazzo R.; Verkindt H.; Legendre B.; Raverdy V.; Cheval L.; Paquot N.; Piette J.; Legrand-Poels S.; Aouadi M.; Pattou F.; Staels B.; Dombrowicz D.

Source : Nature Research